PMID- 32199702
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 81
IP  - 6
DP  - 2020 Jun
TI  - Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in 
      patients with acute leukemia after HLA-matched sibling HSCT.
PG  - 285-292
LID - S0198-8859(20)30039-2 [pii]
LID - 10.1016/j.humimm.2020.03.004 [doi]
AB  - In addition to T cells, NK cells can also participate in the outcome of 
      hematopoietic stem cell transplantation (HSCT) mainly through the interaction 
      between donor killer cell immunoglobulin-like receptors (KIRs) and recipient 
      human leukocyte antigen (HLA) class I molecules. There is a risk of GVHD other 
      than leukemia relapse after allogeneic HSCT that activation of donor NK cells in 
      the absence of appropriate inhibitory ligands will be one of the reasons. To 
      investigate the impact of donor KIRs and recipient KIR/HLA class I combinations 
      on GVHD and leukemia relapse in patients with acute leukemia after HSCT, 100 
      patients with acute leukemia who received HSCT from their HLA-matched siblings 
      were included in this study. Genotypes of 16 KIR genes and two 2DS4 variants 
      (full length and deleted alleles), along with HLA-A/B genotypes, were determined 
      by PCR-SSP. HLA-C genotyping was done with the SSO-Luminex method. Chimerism 
      analysis was done using 16 short tandem repeats (STRs) to detect early leukemia 
      relapse. Acute (a)GVHD occurred in 38 patients, and 16 of them died during the 
      study. None of the recipients showed any sign of leukemia relapse after HSCT. 
      Full donor chimerism was observed in all tested patients during the first year 
      after HSCT. Our results also indicated an increased risk of aGVHD in AA 
      recipients with the C2/Cx, Bw4(+) (or A-Bw4(+)) or HLA-A3(-)/A11(-) genotypes who 
      received HSCT from Bx donors. Our results showed that donor selection based on 
      donor-recipient KIR genotypes and recipient HLA class I status can improve the 
      outcome of HSCT.
CI  - Copyright (c) 2020 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Mansouri, Marzieh
AU  - Mansouri M
AD  - Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Villard, Jean
AU  - Villard J
AD  - Immunology and Transplant Unit, National Reference Laboratory for 
      Histocompatibility (LNRH), Geneva, Switzerland.
FAU - Ramzi, Mani
AU  - Ramzi M
AD  - Hematology and Bone Marrow Transplant Research Center, Shiraz University of 
      Medical Sciences, Shiraz, Iran.
FAU - Alavianmehr, Ali
AU  - Alavianmehr A
AD  - Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Farjadian, Shirin
AU  - Farjadian S
AD  - Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. 
      Electronic address: farjadsh@sums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20200318
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Chimerism
MH  - Female
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - *Genotype
MH  - Graft vs Host Disease/*genetics
MH  - HLA Antigens/metabolism
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Histocompatibility Testing
MH  - Humans
MH  - Killer Cells, Natural/*immunology
MH  - Leukemia/*therapy
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Receptors, KIR/*genetics
MH  - Siblings
MH  - Young Adult
OTO - NOTNLM
OT  - Acute leukemia
OT  - Chimerism
OT  - Graft versus host disease
OT  - Hematopoietic stem cell transplantation
OT  - Human leukocyte antigen
OT  - Killer immunoglobulin-like receptor
EDAT- 2020/03/23 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/03/23 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/03/06 00:00 [revised]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/03/23 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/03/23 06:00 [entrez]
AID - S0198-8859(20)30039-2 [pii]
AID - 10.1016/j.humimm.2020.03.004 [doi]
PST - ppublish
SO  - Hum Immunol. 2020 Jun;81(6):285-292. doi: 10.1016/j.humimm.2020.03.004. Epub 2020 
      Mar 18.